摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-O-benzyl-3,4-O-isopropylidene-D-erythritol (12) and 2-O-benzyl-3,4-O-isopropylidene-D-erythritol | 111462-38-5

中文名称
——
中文别名
——
英文名称
1-O-benzyl-3,4-O-isopropylidene-D-erythritol (12) and 2-O-benzyl-3,4-O-isopropylidene-D-erythritol
英文别名
(2S)-2-(benzyloxy)-2-[(2'R)-2',2'-dimethyl-1',3'-dioxolan-4'-yl]ethanol;(1S,4'R)-1-benzyloxy-1-(2,2-dimethyl-1,3-dioxolane-4-yl)ethan-2-ol;(S)-2-(benzyloxy)-2-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)ethanol;(S)-2-(benzyloxy)-2-[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]ethanol;2-O-benzyl-3,4-O-isopropylidene-D-erythritol;2-O-benzyl-3,4-O-isopropylidene-D-erytritol;(2S,3S)-2-Benzyloxy-3,4-O-isopropylidene-butan-1-OL;(2S)-2-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-2-phenylmethoxyethanol
1-O-benzyl-3,4-O-isopropylidene-D-erythritol (12) and 2-O-benzyl-3,4-O-isopropylidene-D-erythritol化学式
CAS
111462-38-5
化学式
C14H20O4
mdl
——
分子量
252.31
InChiKey
BCACQGHYULTSHT-QWHCGFSZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    18
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.57
  • 拓扑面积:
    47.9
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Total synthesis and the anticancer activity of (+)-spisulosine
    作者:Milica Fabišíková、Miroslava Martinková、Simona Hirková、Jozef Gonda、Martina Bago Pilátová、Gabriela Gönciová
    DOI:10.1016/j.carres.2016.09.010
    日期:2016.11
    The total synthesis of the anticancer agent (+)-spisulosine has been accomplished. The strategy involved a substrate-controlled aza-Claisen rearrangement to establish the erythro-configured amino-alcohol motif followed by deoxygenation to create a methyl side-chain. Subsequent Wittig olefination then permitted the construction of the carbon backbone of the target molecule. To investigate the antiproliferative
    已经完成了抗癌药(+)-spisulosine的全合成。该策略涉及底物控制的aza-Claisen重排以建立赤型构型的氨基醇基序,然后进行脱氧以创建甲基侧链。随后随后的维蒂希烯化反应允许构建靶分子的碳主链。为研究1的抗增殖作用,在一组6种人类恶性细胞系上检查了其生物学特性,并证明了1对至少5种评估系具有显着的抗癌活性,IC50 <1μM(MCF-7,HTC- 116,Caco-2,Jurkat和HeLa)。
  • A Defunctionalization Concept for the Convenient Synthesis of Bis(5-arylfuran-2-yl)methane Scaffolds
    作者:Praveen Kumar Tiwari、Tufan Mukhopadhyay、Indrapal Singh Aidhen
    DOI:10.1002/ejoc.201301319
    日期:2013.12
    The bis(5-arylfuran-2-yl)methane framework has been obtained through defunctionalization of aryl ketones, derived from abundantly available L-(+)-tartaric acid, under the influence of acid. The stereocomponents present in these starting aryl ketones have been found to be insignificant for this transformation.
    双(5-芳基呋喃-2-基)甲烷骨架是通过芳基酮的去官能化获得的,芳基酮衍生自大量可用的L-(+)-酒石酸,在酸的影响下。已经发现这些起始芳基酮中存在的立体组分对于这种转化是微不足道的。
  • Stereoselective allylation for preparation of L-hexose derivatives
    作者:D.R. Williams、Franz D. Klingler
    DOI:10.1016/s0040-4039(01)81010-8
    日期:1987.1
    The reaction of allyltrimethylsilane with α,β-dialkoxyaldehydes is catalyzed by magnesium bromide, and provides for a highly stereoselective allylation which is predicted by α-chelation of the Lewis acid. The observed stereocontrol is opposite to that generally obtained from a variety of common allylation reagents.
    烯丙基三甲基硅烷与α,β-二烷氧基醛的反应被溴化镁催化,并提供了高度立体选择性的烯丙基化,其通过路易斯酸的α-螯合来预测。观察到的立体控制与通常从多种常见的烯丙基化试剂获得的立体控制相反。
  • Synthesis and Glycosidase Inhibitory Activities of Pyrrolidines and Piperidines withN-(Polyhydroxyalkyl) Side Chains
    作者:Sabrina Boutefnouchet、István Moldvai、Eszter Gács-Baitz、Claudia Bello、Pierre Vogel
    DOI:10.1002/ejoc.200700027
    日期:2007.6
    Amidification of L-proline (3) with (+)-(R,R)-6 and ()-(S,S)-tartaric anhydride diacetate (7) gave N-substituted L-proline derivatives 8a,b, respectively. Acids 8a,b were transformed into diesters 9a,b with MeOH/HCl. Similar reactions with methyl (2S,4R)-4 and (2R,4S)-4-acetoxypipecolate (5) led to bicyclic lactams 14a,b and 15a. Compounds 8a,b were converted into N-(trihydroxybutyl)pyrrolidine derivatives
    L-脯氨酸 (3) 与 (+)-(R,R)-6 和 (-)-(S,S)-酒石酸酐二乙酸酯 (7) 的酰胺化分别得到 N-取代的 L-脯氨酸衍生物 8a,b . 用MeOH/HCl将酸8a、b转化为二酯9a、b。与 (2S,4R)-4 和 (2R,4S)-4-乙酰氧基哌可酸甲酯 (5) 的类似反应生成双环内酰胺 14a、b 和 15a。化合物8a、b被转化为N-(三羟基丁基)吡咯烷衍生物8c、d、10a、b和11a、b。(2S,4R)-20a 和 (2R,4S)-4-乙酰氧基-N-[(2S,3S)-1,2,3-三羟基丁基]哌可酸甲酯 (20b) 通过置换 (-)-( 2S,2S)-2-O-benzyl-3,4-O-isopropylidene-1-deoxy-1-iodthreitol (19) 通过 4 和 5。化合物 20a,b 被转化为 (2S,4R,2'S, 2'S)-21a 和 (2R
  • Enantioselective Synthesis of Ethyl 4,5,7,8,9-Penta-O-acetyl-2,6-anhydro- 3-deoxy-D-erythro-L-gluca-nononate: a 2-Monodeoxygenated Derivative of `2-Keto-3-deoxy-D-glycero-D-galacto-nononic Acid'
    作者:Xin Shen、Yu-Lin Wu、Yikang Wu
    DOI:10.1002/(sici)1522-2675(20000510)83:5<943::aid-hlca943>3.0.co;2-h
    日期:2000.5.10
    A study aimed at developing an enantioselective synthesis of the title compound 23, a 2-monodeoxy analogue of;he naturally occurring (+)-2-keto-3-deoxy-D-glycero-D-galacto-2-nononic acid (KDN),is reported. From D-mannose as starting material, the chiral 1,3-diene 10, activated by a silyloxy substituent at C(2), was prepared in six steps (Scheme I). However, the intermediates were often contaminated with varying amounts of by-products arising from overoxidation during cleavage with periodic acid. An alternative route starting from the inexpensive and readily available D-isoascorbic acid (12), though a little longer than the first, satisfactorily circumvented the purification problem and led to the desired dienes 17 in good yields (scheme2). The [Co-II(S.S)-(+)-salen]-catalyzed hetero-Diels-Alder reactions of the aforementioned dienes with ethyl glyoxylate proceeded smoothly at room temperature, giving the dihydropyrano adducts 18 in moderate yields (Scheme 3). Dihydroxylation of 18a followed by reduction of the keto function gave the desired 4,5-trans dihydroxy moiety of the KDN framework (Scheme 4, see 21). The spectroscopic data of the penta-O-acetylated 2-deoxy-KDN ethyl ester 23 were consistent with those reported for the corresponding methyl ester derived from natural KDN.
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐